Robert Knobler is an expert in Dermatology at Medical University of Vienna (Austria). As of October 2026, ScienceLeadR ranks Robert Knobler in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Robert Knobler has authored 369 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 1,120 (community average: 125). How the SLR is computed.

LeadR Profile

Robert Knobler Medical University of Vienna Austria
1 120 ScienceLeadR Reputation 1120
Network Map

Dermatology

Subspecialties: Hematology - Oncology - Pulmonology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026

Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome.
PMID 42842270 — mycosis fungoides, sezary syndrome, lymphoma, disease progression, skin diseases, diagnosis
JAMA Dermatol20260
Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
PMID 41651641 — mycosis fungoides, safety, progression-free survival, sezary syndrome, disease progression, maintenance, drug-related side effects and adverse reactions, therapeutics, hematologic diseases
Lancet Haematol20260
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.
PMID 40663780 — hematology, lymphoma
Blood20251
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT".
PMID 40319676 — mycosis fungoides, safety, sezary syndrome, neoplasms, therapeutics
Eur J Cancer20250
Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate.
PMID 39945859 — graft rejection, cells, photopheresis, lung, blood, oxylipins, sphingosine, transplants, fibroblasts, therapeutics, plasma, fatty acids
Inflamm Res20250

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Study Chair: 2

By phase:

Phase 2 5
N/A 1
Phase 3 1

By status:

Completed 3
Terminated 2
Recruiting 1
Withdrawn 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map